Glucocorticoid-induced osteoporosis

Trends in Endocrinology and Metabolism

Volumn 11, Issue 3, 2000, Pages 79-85

  Manelli, Filippo ^a   Giustina, Andrea ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM ION; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; HYDROCORTISONE; PAMIDRONIC ACID; PARATHYROID HORMONE; RISEDRONIC ACID; SALCATONIN; TRICHLORMETHIAZIDE; VITAMIN D;

BONE METABOLISM; CALCIUM ABSORPTION; DRUG INDUCED DISEASE; FRACTURE; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; BONE AND BONES; BONE RESORPTION; GLUCOCORTICOIDS; HUMANS; OSTEOGENESIS; OSTEOPOROSIS;

EID: 0034066366     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(00)00234-4     Document Type: Review

References (42)

1. Silvestrini G.et al. Cytochemical demonstration of the glucocorticoid receptor in skeletal cells of the rat. Endocr. Res. 25:1999;117-128.
2. Weinstein R.S.et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102:1998;274-282.
3. Chen J.et al. Regulation of bone sialoprotein and osteopontin mRNA expression by dexamethasone and 1,25-dihydroxyvitamin D3 in rat bone organ cultures. Connect. Tissue Res. 34:1996;41-51.
4. Canalis E. Inhibitory actions of glucocorticoids on skeletal growth. Is local insulin-like growth factor I to blame? Endocrinology. 139:1998;3041-3042.
5. Dempster D.W.et al. Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis. J. Endocrinol. 154:1997;397-406.
6. Diamond T.et al. Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. Br. J. Haematol. 97:1997;641-648.
7. Gennari C. Differential effect of glucocorticoids on calcium absorption and bone mass. Br. J. Rheumatol. 32(Suppl. 2):1993;11-14.
8. Luckert B.P., Raisz L.G. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann. Intern. Med. 112:1990;352-364.
9. Reid I.R. Glucocorticoid osteoporosis - mechanisms and management. Eur. J. Endocrinol. 137:1997;209-217.
10. Cosman F.et al. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J. Bone Miner. Res. 9:1994;1097-2005.
11. Giustina A., Wehrenberg W.B. The role of glucocorticoids in the regulation of growth hormone secretion. Trends Endocrinol. Metab. 3:1992;306-311.
12. Ohlsson C.et al. Growth hormone and bone. Endocr. Rev. 19:1998;55-79.
13. Bergendahl M., Veldhuis J.D. Altered pulsatile gonadotropin signaling in nutritional deficiency in the male. Trends Endocrinol. Metab. 6:1995;145-159.
14. Eastell R.et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J. Intern. Med. 244:1998;271-292.
15. Laan R.F.et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann. Intern. Med. 119:1993;963-968.
16. Pearce G.et al. Corticosteroid-induced bone loss in men. J. Clin. Endocrinol. Metab. 83:1998;801-806.
17. Lems W.F.et al. Changes in (marker of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 55:1996;288-293.
18. Wuster C.et al. Quantitative ultrasonometry (QUS) for the evaluation of osteoporosis risk: reference data for various measurement sites, limitations and application possibilities. Exp. Clin. Endocrinol. Diabetes. 106:1998;277-288.
19. Manelli F.et al. Bone density and elasticity in glucocorticoid-induced osteoporosis: examination by ultrasonography at the phalanxes of the hand. Osteoporos. Int. 9:1999;S21. (abstr.).
20. Lo Cascio V.et al. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort. Calcif. Tissue Int. 62:1998;199-204.
21. Krogsgaard M.R.et al. Changes in bone mass during low dose corticosteroid treatment in patients with polymialgia rheumatica: a double blind, prospective comparison between prednisolone and deflazacort. Ann. Rheum. Dis. 55:1996;143-146.
22. Buckley L.M.et al. Calcium and vitamin D supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double blind, placebo-controlled trial. Ann. Intern. Med. 125:1996;961-968.
23. Ringe J.D. Active vitamin D metabolites in glucocorticoid-induced osteoporosis. Calcif. Tissue Int. 60:1997;124-127.
24. Adachi J.D.et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow-up. J. Rheumatol. 23:1996;995-1000.
25. Fritz P.C.et al. Tamoxifen attenuates the effects of exogenous glucocorticoid on bone formation and growth in piglets. Endocrinology. 139:1998;3399-3403.
26. Adachi J.D.et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br. J. Rheumatol. 36:1997;255-259.
27. Saag K.G.et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. New Engl. J. Med. 339:1998;292-299.
28. Lems W.F.et al. Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis. Osteoporos. Int. 7:1997;575-582.
29. Need A.G. Corticosteroids and osteoporosis. Aust. New Zealand J. Med. 17:1987;267-272.
30. Reid I.R.et al. Testosterone therapy in glucocorticoid-treated men. Arch. Intern. Med. 156:1996;1173-1177.
31. Lukert B.P.et al. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced boss loss. J. Bone Miner. Res. 7:1992;1063-1069.
32. Giustina A.et al. Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J. Clin. Endocrinol. Metab. 80:1995;122-129.
33. Lane N.E.et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102:1998;1627-1633.
34. Resche-Rigon M., Gronemeyer H. Therapeutic potential of selective modulators of nuclear receptor action. Curr. Opin. Chem. Biol. 2:1998;501-507.
35. Bland R.et al. Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. J. Endocrinol. 161:1999;455-464.
36. Yamada H. Long-term effect of 1alpha-hydroxyvitamin D, calcium and thiaxoide administration on glucocorticoid-induced osteoporosis. Nippon Naibunpi Gakki Zashi. 65:1989;603-614.
37. Luengo M.et al. Prevention of further bone mass loss by nasal calcitonin in patients on long-term glucocorticoid therapy for asthma: a two-year follow-up study. Thorax. 49:1994;1099-1102.
38. Shane E.et al. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J. Heart Lung Transplant. 17:1998;1089-1096.
39. Adachi J.D.et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. New Engl. J. Med. 337:1997;382-387.
40. Sebaldt R.J.et al. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid-induced osteoporosis. J. Rheumatol. 26:1999;1545-1549.
41. Cortet B.et al. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Rev. Rheum. Engl. Ed. 66:1999;214-219.
42. Reid D.M. The role of risedronate in the management of postmenopausal and corticosteroid-induced osteoporosis: an initial assessment. Today's Ther. Trends. 17:1999;339-366.